Researchers at the Icahn School of Medicine at Mount Sinai reported preclinical data showing IL‑12‑producing CAR T cells that target tumor‑associated macrophages (TAMs) remodel the tumor microenvironment and extend survival in aggressive metastatic ovarian and lung cancer mouse models. The approach aims to clear the immunosuppressive barrier TAMs create so endogenous immune responses and additional therapies can act. The team published results in Cancer Cell and described the strategy as a ‘Trojan horse’—CAR T cells kill or reprogram macrophages while releasing IL‑12 to stimulate local immunity. The work provides a new preclinical pathway for CAR T approaches in solid tumors, but clinical translation will require safety evaluation of intratumoral cytokine production and on‑target, off‑tumor macrophage effects.